Predicting Biologic Immunogenicity Risk Through Protein Aggregation Pathway Modeling

Speciality: Others


Speaker:

Dimple Jain | HCP

Description:

Welcome to the podcast. Today, we’re exploring how scientists predict immunogenicity risk in biologic drugs using protein aggregation pathway modeling. Biologics, like therapeutic antibodies, can sometimes trigger unwanted immune responses in patients. One key factor is protein aggregation, where proteins clump together and may become more visible to the immune system. By modeling how these aggregates form, researchers can identify high-risk biologics early in development. This approach combines computational simulations with laboratory data to predict which formulations may cause immune reactions. Ultimately, protein aggregation pathway modeling helps drug developers reduce immunogenicity risk, leading to safer and more effective biologic therapies for patients. Thanks for listening.

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot